FCM
BSX icon

Fairbanks Capital Management’s Boston Scientific BSX Stock Holding History

Fairbanks Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
24,508
-363
-1% -$19.7K 0.62% 38
2026
Q1 		$1.56M Sell
24,871
-599
-2% -$47.9K 0.98% 29
2025
Q4 		$2.43M Sell
25,470
-244
-0.9% -$23.9K 1.34% 26
2025
Q3 		$2.51M Buy
25,714
+21
+0.1% +$2.17K 1.36% 25
2025
Q2 		$2.76M Buy
25,693
+1,609
+7% +$163K 1.57% 22
2025
Q1 		$2.43M Sell
24,084
-6,133
-20% -$618K 1.56% 23
2024
Q4 		$2.7M Buy
30,217
+748
+3% +$65.8K 1.68% 21
2024
Q3 		$2.47M Buy
29,469
+1,644
+6% +$130K 1.55% 24
2024
Q2 		$2.14M Buy
27,825
+658
+2% +$48.2K 1.41% 26
2024
Q1 		$1.86M Sell
27,167
-423
-2% -$27.2K 1.28% 27
2023
Q4 		$1.59M Buy
27,590
+1,448
+6% +$77.3K 1.14% 30
2023
Q3 		$1.38M Sell
26,142
-1,243
-5% -$65.2K 1.16% 27
2023
Q2 		$1.48M Sell
27,385
-6,015
-18% -$314K 1.15% 26
2023
Q1 		$1.67M Sell
33,400
-1,346
-4% -$63.4K 1.33% 22
2022
Q4 		$1.61M Sell
34,746
-118
-0.3% -$5.11K 1.43% 22
2022
Q3 		$1.35M Sell
34,864
-426
-1% -$17.1K 1.26% 26
2022
Q2 		$1.31M Sell
35,290
-940
-3% -$38.3K 1.15% 27
2022
Q1 		$1.6M Sell
36,230
-18
-0% -$780 1.19% 26
2021
Q4 		$1.54M Buy
36,248
+58
+0.2% +$2.44K 1.12% 31
2021
Q3 		$1.57M Buy
36,190
+1,113
+3% +$49.2K 1.28% 30
2021
Q2 		$1.5M Buy
35,077
+1,770
+5% +$74.5K 1.18% 32
2021
Q1 		$1.29M Buy
33,307
+5,081
+18% +$192K 1.05% 34
2020
Q4 		$1.01M Buy
28,226
+9,881
+54% +$356K 0.91% 35
2020
Q3 		$701K Hold
18,345
– – 0.7% 44
2020
Q2 		$729K Buy
18,345
+553
+3% +$19.9K 0.71% 42
2020
Q1 		$581K Buy
17,792
+6,670
+60% +$261K 0.76% 41
2019
Q4 		$503K Buy
11,122
+3,509
+46% +$147K 0.52% 46
2019
Q3 		$310K Buy
+7,613
New +$323K 0.32% 50

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fairbanks Capital Management's BSX Position: Q2 2026 in Review

Fairbanks Capital Management reduced its Boston Scientific (BSX) stake by 1.5% in Q2 2026, selling an estimated $19.7K and leaving 24,508 shares worth $1.05M. The position accounts for 0.62% of the portfolio, ranked #38.

Fairbanks Capital Management first reported a position in BSX in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.76M in Q2 2025. 1,478 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Fairbanks Capital Management held 24,508 shares of Boston Scientific worth $1.05M as of Q2 2026.
  • Fairbanks Capital Management sold 363 Boston Scientific shares in Q2 2026, an estimated $19.7K.
  • Boston Scientific made up 0.62% of Fairbanks Capital Management's portfolio in Q2 2026, its #38 holding.
  • Fairbanks Capital Management first reported a position in Boston Scientific in Q3 2019 and has held it in 28 quarters since.
  • Fairbanks Capital Management's Boston Scientific position peaked at $2.76M in Q2 2025.
  • 1,478 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Fairbanks Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.